Katharina J. Wenger1, Elke Hattingen1, Joachim P. Steinbach2, Johannes Rieger2,3, Martin Voss2, and Ulrich Pilatus1
1Institute of Neuroradiology, University Hospital, Goethe-University Frankfurt, Frankfurt, Germany, 2Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe-University Frankfurt, Frankfurt, Germany, 3Institute of Neurooncology, University Hospital Tübingen, Tübingen, Germany
Synopsis
Inhibition of glycolysis by decreasing blood
glucoses levels and increasing ketone bodies (KB) could force tumor cells to shift their
metabolism towards potentially impaired mitochondria. The aim of this study was to explore the
combination of six days of calorie restricted ketogenic diet (crKD) and three
days of fasting (as a possible radiosensitizer) with a re-irradiation therapy
in patients with recurrent glioblastoma. Intracerebral concentrations of KB as well as pHi
and ATP were non-invasively monitored using MR-Spectroscopy.
We were able to show evidence of intratumoral acetone using 1H-MRS
in some patients with malignant glioma at day 6 of crKD/fasting. Changes in pHi
and ATP during crKD/fasting will remain subject to preclinical studies.
Introduction
Despite multimodal treatment options, glioblastoma
continues to carry a poor prognosis. It is therefore of high interest to find
combination therapies. While normal neurons and glial cells can metabolize
either ketone bodies (KB) or glucose, malignant brain tumor cells might lack this
metabolic flexibility due to impaired mitochondrial function (1–3). Inhibition of
glycolysis by decreasing blood glucoses levels and increasing KB, could force tumor
cells to shift their metabolism towards the impaired mitochondria. Tumors cells
maintain a slightly alkaline intracellular pH (pH
i) compared to
normal cells through changes in the expression of cellular membrane ion transport
channels and the CO
2/HCO
3-buffering system (4). The aim of this
study was to explore the combination of six days of calorie restricted
ketogenic diet (crKD) and three days of fasting (as a possible radiosensitizer)
with a re-irradiation therapy in patients with recurrent glioblastoma. Intracerebral
concentrations of KB as well as pH
i and ATP were non-invasively
monitored using MR-Spectroscopy.
Methods
This report is based on a prospective multicentric,
non-blinded, randomized study, including an extended MRS protocol (1H
decoupled 31P MRSI with 3D CSI and 2D 1H CSI, Fig.1) at a
3T clinical scanner. Study population consisted of patients with recurrent
glioblastoma and indication for re-irradiation therapy. 50 patients enrolled at
all centers were randomized (1:1) in two groups: Group A keeping a ketogenic
diet with calorie restriction (21-23 kcal/kg/day) for nine days, including
three days of fasting (0 kcal/day) and group B keeping a balanced diet over the
same period. RT was performed on day 4-8 (5 x 4 Gy). 32 patients received MRS
examination at baseline (day-1) and 23/32 on day 6 (Fig.3). Registration to 3D-anatomical data was
performed with an in-house software tool scripted in Matlab. Voxels were
selected from the area of recurrent tumor and on the contralateral hemisphere
in NAWM (control). Analysis of proton data was performed using LCModel and phosphorous
data were analyzed with jMRUI (AMARES) (5, 6). All spectra were
inspected for quality. The basis set for LCModel including 3-hydroxybutyrate
(βOHB), acetone (Ac) and acetoacetate (AcAc) was simulated using the NMRScope-B
plugin implemented in jMRUI (7) and tested on phantom
data (Fig.5). Results were
considered to be significant at p<0.05 using a non-parametric t-test.Results
Patient characteristics and treatment are summarized in Fig.3. 17/25
patients in group A achieved a serum ketone level of >0.5 mmol/l at day 6
during crKD/fasting (dropout: 4 patients). Overall dietary requirements were
well tolerated. There was a significant difference in serum ketone levels at
day 6 between both groups. KB were detected within tumor tissue in two patients
of group A at day 6 with an estimated standard deviation (%SD) ≤30% (LCModel). Both
patients displayed an acetone signal at 2.22 ppm which was quantified. One
of these patients correspondingly showed a high serum ketone level of 4.5
mmol/l. As expected, for both groups, pHi was significantly lower in
control voxels than in tumor voxels (day 6 Group A: p=0.007, Group B: p=0.018).
Neither pHi nor ATP levels showed significant changes in control
voxels of either group. Group A exhibited a significant increase in pHi
in tumor voxels comparing baseline levels to day 6 during crKD/fasting
(p=0.027), while there were no changes reported for Group B. In both groups ATP
levels were stable (Fig.4). With eight patients still censored overall survival
(OS) and progression free survival analysis is pending.Discussion
Even with elevated ketone serum levels in most patients in group A, MRS-detection
of Acn was only seen within tumor tissue in two patients. A lack in correlation
to serum ketone levels and late appearance of brain changes has been previously
reported, even though we were able to detect intracerebral KB as early as day 6
of crKD/fasting (8) The fact that Acn
was detected in tumor tissue only might be due to impaired BBB (9). Recently, the
hypothesis that brain tumors are metabolically inflexible has been contradicted
in two rat glioma models with upregulation of the ketone-body monocarboxylate
transporter, facilitating uptake and oxidation of KB in tumor cells (10). The proposed
metabolic flexibility might lead to KB oxidation and a shift towards the somewhat impaired mitochondria. A possible
result could be improved energy resources for active transport of H+-equivalents,
resulting in an even more alkaline pHi. This might support tumor
metabolism and lead to a lack of improvement in OS for Group A.Conclusion
We were able to show evidence of intratumoral Acn
using 1H-MRS in some patients with malignant glioma at day 6 of
crKD/fasting. Changes in pHi and ATP during crKD/fasting will remain
subject to preclinical studies.Acknowledgements
No acknowledgement found.References
1. Kiebish MA, Han X, Cheng H,
Seyfried TN. In vitro growth environment produces lipidomic and electron
transport chain abnormalities in mitochondria from non-tumorigenic astrocytes
and brain tumours. ASN Neuro. 2009;1(3).
doi:10.1042/AN20090011.
2. Maurer GD, Brucker DP, Bähr O,
et al. Differential utilization of ketone
bodies by neurons and glioma cell lines: a rationale for ketogenic diet as
experimental glioma therapy. BMC Cancer. 2011;11:315.
doi:10.1186/1471-2407-11-315.
3. Oudard S, Boitier E, Miccoli
L, Rousset S, Dutrillaux B, Poupon MF. Gliomas are driven by glycolysis:
putative roles of hexokinase, oxidative phosphorylation and mitochondrial
ultrastructure. Anticancer Res.
1997;17(3C):1903-1911.
4. Marathe K, McVicar N, Li A,
Bellyou M, Meakin S, Bartha R. Topiramate induces acute intracellular
acidification in glioblastoma. J
Neurooncol. 2016;130(3):465-472. doi:10.1007/s11060-016-2258-y.
5. Naressi A, Couturier C,
Castang I, Beer R de, Graveron-Demilly D. Java-based graphical user interface
for MRUI, a software package for quantitation of in vivo/medical magnetic
resonance spectroscopy signals. Comput
Biol Med. 2001;31(4):269-286.
6. Vanhamme, van den Boogaart A,
van Huffel S. Improved method for accurate and efficient quantification of MRS
data with use of prior knowledge. J
Magn Reson. 1997;129(1):35-43.
7. Starcuk Z, Strbak O,
Starcukova J, Graveron-Demilly D. Simulation of steady state free precession
acquisition mode in coupled spin systems for fast MR spectroscopic imaging.
In: 2008 IEEE International Workshop on Imaging Systems and Techniques: IEEE;
2008 - 2008:302-306.
8. Artzi M, Liberman G, Vaisman
N, et al. Changes in cerebral metabolism during ketogenic diet in patients
with primary brain tumors: 1H-MRS study. J Neurooncol. 2017;132(2):267-275. doi:10.1007/s11060-016-2364-x.
9. Musa-Veloso K. Non-invasive
detection of ketosis and its application in refractory epilepsy. Prostaglandins Leukot Essent Fatty Acids.
2004;70(3):329-335. doi:10.1016/j.plefa.2003.08.025.
10. Feyter HM de, Behar KL, Rao JU,
et al. A ketogenic diet increases transport and oxidation of ketone bodies in
RG2 and 9L gliomas without affecting tumor growth. Neuro-oncology. 2016;18(8):1079-1087.
doi:10.1093/neuonc/now088.